This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's How to Find Top-Ranked Stocks Under $10 to Buy
by Benjamin Rains
Here are 5 stocks of the over 30 highly-ranked stocks trading under $10 a share that made it through this week's screen...
Dynavax Technologies Corporation (DVAX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Dynavax Technologies Corporation (DVAX).
Dynavax Technologies (DVAX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -4.76% and 4.94%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Dynavax Technologies Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Dynavax Technologies Corporation (DVAX) has been struggling lately, but the selling pressure may be coming to an end soon.
Dynavax (DVAX) to Cut Jobs and Focus on Vaccine Business
by Zacks Equity Research
Dynavax (DVAX) announces restructuring measures to focus on vaccine business. The CEO of the company will retire on Aug 1, 2019.
Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 7.46% and -3.94%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Dynavax Technologies (DVAX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dynavax Technologies (DVAX) Q3 Earnings Preview: What to Watch Ahead of the Release
by Zacks Equity Research
Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dynavax (DVAX) Catches Eye: Stock Jumps 9.8%
by Zacks Equity Research
Dynavax (DVAX) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Dynavax Technologies (DVAX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -6.78% and -24.23%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
5 of the Best-Performing Biotech Stocks of 2017
by Arpita Dutt
With 2017 coming to an end, it is time to take a look at the performance of the biotech sector and some of the best-performing biotech stocks including XOMA (XOMA).
Biotech Stock Roundup: Dynavax Vaccine Gets FDA Nod, Loxo Inks Deal with Bayer
by Arpita Dutt
Regulatory actions and licensing and collaboration agreements were the key highlights this week with companies like Loxo Oncology (LOXO) remaining in the limelight.
Options Traders Expect Huge Moves in Dynavax (DVAX) Stock
by Zacks Equity Research
Dynavax (DVAX) needs investors to pay close attention to the stock based on moves in the options market lately.
Biotech Stock Roundup: Regeneron Delivers Strong Q3 Results, Cellectis Clinical Hold Lifted
by Arpita Dutt
While focus remained on Regeneron's (REGN) Q3 earnings, Dicerna was also in the news related to its collaboration agreement with Boehringer Ingelheim.
The Zacks Analyst Blog Highlights: Keryx Biopharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies, Heron Therapeutics and Ultragenyx Pharmaceutical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Keryx Biopharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies, Heron Therapeutics and Ultragenyx Pharmaceutical
5 Biotech and Pharma Stocks with Key FDA Catalysts this November
by Arpita Dutt
Here is a look at five biotech and pharma stocks including Dynavax (DVAX) that have an important regulatory event lined up this month.
Best Sector ETF of Q3 and its Top-Performing Stocks
by Sweta Killa
Inside the top performing stocks of top U.S.-focused ETF of Q3.
Are Options Traders Betting on a Big Move in Dynavax (DVAX) Stock?
by Zacks Equity Research
Investors in Dynavax Technologies Corporation (DVAX) need to pay close attention to the stock based on moves in the options market lately.
Biotech Stock Roundup: Q2 Earnings from Regeneron, Kite & More, FibroGen Up on IPF Data
by Arpita Dutt
Regeneron (REGN) and several other biotech companies reported Q2 earnings while FibroGen hit a 52-week high on promising idiopathic pulmonary fibrosis (IPF) data.
Dynavax Technologies (DVAX) Catches Eye: Stock Adds 11.2% in Session
by Zacks Equity Research
Dynavax Technologies Corporation (DVAX) was a big mover last session, as the company saw its shares rise over 11% on the day.
Biotech Stock Roundup: Q2 Earnings from Gilead, CELG & More, Dynavax Up on Panel Vote
by Arpita Dutt
Companies like Gilead (GILD) topped expectations in the second quarter while Dynavax shot up on a positive FDA advisory panel vote.
Company News For August 1, 2017
by Zacks Equity Research
Companies in the news are: DVAX,SNI,MDT,CAH,DISC,LH
Dynavax (DVAX) Shares Jump 75% after FDA Committee Approval
by Megan Sanks
Dynavax Technologies Corp. (DVAX) shares rocketed 75% in morning trading on Monday after a Food and Drug Administration committee approved the company's hepatitis B vaccination.
Options Traders Expect Huge Moves in Dynavax Technologies (DVAX) Stock
by Zacks Equity Research
Dynavax Technologies (DVAX) needs Investors to pay close attention to the stock based on moves in the options market lately.
Dynavax Technologies (DVAX) Catches Eye: Stock Gains 6.6%
by Zacks Equity Research
Dynavax Technologies Corporation (DVAX) shares rose almost 7% in the last trading session.